CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
guanfacine +1 moredrug
Likely dose
guanfacine 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00773357
NCT00773357Phase 2Completed
CompareCT.gov

Modeling Stress-precipitated Smoking Behavior for Medication Development

Yale University·interventional·Posted Oct 16, 2008·Updated Aug 3, 2022

In Brief

A Phase 2 clinical trial evaluating guanfacine and placebo for Smoking. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The purpose of this study is to examine whether guanfacine will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Office of Research on Women's Health (ORWH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 16, 2008
Enrollment StartOct 1, 2008
Primary CompletionJul 31, 2021
TodayJul 2, 2026
Enrollment to primary: 12.8 yearsPosted 17.7 years ago

Interventions

guanfacinedrug

3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.

placebodrug

placebo